MeSH term
Frequency | Condition_Probility | Base Sequence | 5 | 0.0 |
Comparative Study | 4 | 0.0 |
Humans | 27 | 0.0 |
Metalloendopeptidases/*genetics | 3 | 3.0 |
Molecular Sequence Data | 6 | 0.0 |
Research Support, Non-U.S. Gov't | 10 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Transcription Initiation Site | 2 | 1.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Aged | 3 | 0.0 |
Diffusion | 2 | 2.0 |
Female | 9 | 0.0 |
Middle Aged | 3 | 0.0 |
Solubility | 2 | 0.0 |
Animals | 10 | 0.0 |
Cell Line | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Exons | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 5 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
Metalloendopeptidases/analysis | 2 | 22.0 |
English Abstract | 5 | 0.0 |
Male | 6 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Cyclophosphamide/pharmacology | 2 | 5.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Adolescent | 3 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 4 | 0.0 |
Child | 4 | 0.0 |
Child, Preschool | 3 | 0.0 |
Cyclophosphamide/administration & dosage | 4 | 1.0 |
Cytarabine/administration & dosage | 2 | 2.0 |
Doxorubicin/administration & dosage | 4 | 2.0 |
Methotrexate/administration & dosage | 2 | 2.0 |
Vincristine/administration & dosage | 2 | 1.0 |
Mice | 4 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Mice, Nude | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Cisplatin/administration & dosage | 2 | 0.0 |
Drug Administration Schedule | 2 | 0.0 |
Adult | 5 | 0.0 |
Time Factors | 2 | 0.0 |
Amino Acid Sequence | 2 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Metalloendopeptidases/*metabolism | 2 | 2.0 |
Fluorouracil/administration & dosage | 2 | 1.0 |
Blotting, Northern | 2 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
